Biology of Bladder Cancer : From Molecular Insights to Clinical Strategies / / edited by Margaret A. Knowles, Lars Dyrskjøt
| Biology of Bladder Cancer : From Molecular Insights to Clinical Strategies / / edited by Margaret A. Knowles, Lars Dyrskjøt |
| Autore | Knowles Margaret A |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (946 pages) |
| Disciplina |
571.978
616.994 |
| Altri autori (Persone) | DyrskjøtLars |
| Soggetto topico |
Cancer
Oncology Oncogenes Tumor markers Cancer - Treatment Cancer Biology Cancers Tumour Biomarkers Cancer Therapy |
| ISBN |
9783031685057
3031685059 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I. Fundamentals of Bladder Cancer -- Chapter 1. Epidemiology of Bladder Cancer -- Chapter 2. Genetic Predisposition to Bladder Cancer -- Chapter 3. Human Urothelium -- Chapter 4. Bladder Cancer Pathology -- Chapter 5. Overview of Standard Therapy of Non Muscle-Invasive Bladder Cancer -- Chapter 6. Overview of Standard Therapy of Muscle-Invasive Bladder Cancer -- Part II. Molecular Genetics and Oncogenesis in Bladder Cancer -- Chapter 7. From Normalcy to Neoplasia: Mutational Events during Bladder Tumor Evolution -- Chapter 8. Cell Cycle Regulators as Oncogenic Drivers in Bladder Cancer -- Chapter 9. DNA Repair Pathway Alterations in Bladder Cancer -- Chapter 10. DNA Methylation and Chromatin Regulators in Bladder Cancer -- Part III. Pathogenesis and Microenvironment Dynamics in Bladder Cancer -- Chapter 11. Molecular Pathogenesis: Field Cancerization and Clonal Evolution in Urothelial Cancer Initiation and Progression -- Chapter 12. The Bladder Tumor Microenvironment -- Part IV. Molecular and Histological Subtypes of Bladder Cancer -- Chapter 13. Molecular Subtypes of Non-Muscle-Invasive Bladder Cancer -- Chapter 14. Molecular Subtypes of Muscle-Invasive Bladder Cancer -- Chapter 15. Molecular Features of Divergent Differentiation and Histological Subtypes in Bladder Cancer -- Part V. Experimental Models of Bladder Cancer -- Chapter 16. The Emerging Landscape of Mouse Bladder Cancer Models -- Chapter 17. In Vitro Bladder Cancer Models -- Part VI. Biomarkers for Diagnosis and Treatment of Bladder Cancer -- Chapter 18. Urine Biomarkers for Bladder Cancer Diagnosis and Screening -- Chapter 19. Blood-Based Biomarkers for Bladder Cancer Diagnosis and Prognosis -- Chapter 20. Mechanisms and Biomarkers of Response to BCG and Chemotherapy in Bladder Cancer -- Part VII. Therapeutic Application based on Molecular Insights -- Chapter 21. New Treatment Approaches in Non-Muscle-Invasive Bladder Cancer -- Chapter 22. New Treatment Approaches in Muscle-Invasive Bladder Cancer -- Chapter 23. Targeting the Immune Checkpoint in Bladder Cancer -- Part VIII. Future Directions in Bladder Cancer Research -- Chapter 24. Future Directions in Bladder Cancer Research and Clinical Implications. |
| Record Nr. | UNINA-9910946349603321 |
Knowles Margaret A
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genetic analysis of tumour suppression [[electronic resource]]
| Genetic analysis of tumour suppression [[electronic resource]] |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1989 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina |
616.99
616.994042 |
| Altri autori (Persone) |
BockGregory
MarshJoan |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Tumors - Genetic aspects
Gene expression Oncogenes |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-34759-4
9786612347597 0-470-51375-6 0-470-51376-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENETIC ANALYSIS OF TUMOUR SUPPRESSION; Contents; Participants; Introduction; Epidemiology of genetically determined cancer; Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis; Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line; Lymphoid neoplasia and the control of haemopoietic differentiation; General discussion I; Loss of genetic information in cancer; General discussion II; The molecular basis of retinoblastomas; General discussion Ill
Proviral position effects: possible probes for genes that suppress transcriptionGeneral discussion IV; Flat revertants of EJ human bladder carcinoma cells show two different mechanisms of reversion; A genetic basis for tumour suppression; Molecular basis for the regulation of cell fate by the lethal (2) giant larvae tumour suppressor gene of Drosophila melanogaster; Suppression of genetic melanoma in the fish Xiphophorus; The biology of tumour suppression; General discussion V; Cell differentiation and tumour suppression; General discussion VI; Final discussion; Index of contributors Subject index |
| Record Nr. | UNINA-9910144560503321 |
| Chichester ; ; New York, : Wiley, 1989 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genetic analysis of tumour suppression [[electronic resource]]
| Genetic analysis of tumour suppression [[electronic resource]] |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1989 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina |
616.99
616.994042 |
| Altri autori (Persone) |
BockGregory
MarshJoan |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Tumors - Genetic aspects
Gene expression Oncogenes |
| ISBN |
1-282-34759-4
9786612347597 0-470-51375-6 0-470-51376-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENETIC ANALYSIS OF TUMOUR SUPPRESSION; Contents; Participants; Introduction; Epidemiology of genetically determined cancer; Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis; Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line; Lymphoid neoplasia and the control of haemopoietic differentiation; General discussion I; Loss of genetic information in cancer; General discussion II; The molecular basis of retinoblastomas; General discussion Ill
Proviral position effects: possible probes for genes that suppress transcriptionGeneral discussion IV; Flat revertants of EJ human bladder carcinoma cells show two different mechanisms of reversion; A genetic basis for tumour suppression; Molecular basis for the regulation of cell fate by the lethal (2) giant larvae tumour suppressor gene of Drosophila melanogaster; Suppression of genetic melanoma in the fish Xiphophorus; The biology of tumour suppression; General discussion V; Cell differentiation and tumour suppression; General discussion VI; Final discussion; Index of contributors Subject index |
| Record Nr. | UNINA-9910830198903321 |
| Chichester ; ; New York, : Wiley, 1989 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genetic analysis of tumour suppression
| Genetic analysis of tumour suppression |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1989 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina |
616.99
616.994042 |
| Altri autori (Persone) |
BockGregory
MarshJoan |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Tumors - Genetic aspects
Gene expression Oncogenes |
| ISBN |
9786612347597
9781282347595 1282347594 9780470513750 0470513756 9780470513767 0470513764 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENETIC ANALYSIS OF TUMOUR SUPPRESSION; Contents; Participants; Introduction; Epidemiology of genetically determined cancer; Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis; Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line; Lymphoid neoplasia and the control of haemopoietic differentiation; General discussion I; Loss of genetic information in cancer; General discussion II; The molecular basis of retinoblastomas; General discussion Ill
Proviral position effects: possible probes for genes that suppress transcriptionGeneral discussion IV; Flat revertants of EJ human bladder carcinoma cells show two different mechanisms of reversion; A genetic basis for tumour suppression; Molecular basis for the regulation of cell fate by the lethal (2) giant larvae tumour suppressor gene of Drosophila melanogaster; Suppression of genetic melanoma in the fish Xiphophorus; The biology of tumour suppression; General discussion V; Cell differentiation and tumour suppression; General discussion VI; Final discussion; Index of contributors Subject index |
| Record Nr. | UNINA-9911019225203321 |
| Chichester ; ; New York, : Wiley, 1989 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
How to win the Nobel Prize [[electronic resource] ] : an unexpected life in science. / / J. Michael Bishop
| How to win the Nobel Prize [[electronic resource] ] : an unexpected life in science. / / J. Michael Bishop |
| Autore | Bishop J. Michael <1936-> |
| Edizione | [1st Harvard University Press pbk. ed.] |
| Pubbl/distr/stampa | Cambridge, MA ; ; London, : Harvard University Press, 2004 |
| Descrizione fisica | xiii, 271 p. : ill |
| Disciplina | 610.92 |
| Collana | The Jerusalem-Harvard lectures |
| Soggetto topico |
Medical scientists - United States
Oncogenes Nobel Prizes |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-674-02097-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Contents -- List of Illustrations -- Preface -- 1. The Phone Call -- 2. Accidental Scientist -- 3. People and Pestilence -- 4. Opening the Black Box of Cancer -- 5. Paradoxical Strife -- Notes -- Credits -- Index |
| Record Nr. | UNINA-9910455133003321 |
Bishop J. Michael <1936->
|
||
| Cambridge, MA ; ; London, : Harvard University Press, 2004 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
How to win the Nobel Prize [[electronic resource] ] : an unexpected life in science. / / J. Michael Bishop
| How to win the Nobel Prize [[electronic resource] ] : an unexpected life in science. / / J. Michael Bishop |
| Autore | Bishop J. Michael <1936-> |
| Edizione | [1st Harvard University Press pbk. ed.] |
| Pubbl/distr/stampa | Cambridge, MA ; ; London, : Harvard University Press, 2004 |
| Descrizione fisica | xiii, 271 p. : ill |
| Disciplina | 610.92 |
| Collana | The Jerusalem-Harvard lectures |
| Soggetto topico |
Medical scientists - United States
Oncogenes Nobel Prizes |
| ISBN | 0-674-02097-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Contents -- List of Illustrations -- Preface -- 1. The Phone Call -- 2. Accidental Scientist -- 3. People and Pestilence -- 4. Opening the Black Box of Cancer -- 5. Paradoxical Strife -- Notes -- Credits -- Index |
| Record Nr. | UNINA-9910778455503321 |
Bishop J. Michael <1936->
|
||
| Cambridge, MA ; ; London, : Harvard University Press, 2004 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
How to win the Nobel Prize : an unexpected life in science. / / J. Michael Bishop
| How to win the Nobel Prize : an unexpected life in science. / / J. Michael Bishop |
| Autore | Bishop J. Michael <1936-> |
| Edizione | [1st Harvard University Press pbk. ed.] |
| Pubbl/distr/stampa | Cambridge, MA ; ; London, : Harvard University Press, 2004 |
| Descrizione fisica | xiii, 271 p. : ill |
| Disciplina | 610.92 |
| Collana | The Jerusalem-Harvard lectures |
| Soggetto topico |
Medical scientists - United States
Oncogenes Nobel Prizes |
| ISBN |
9780674020979
0674020979 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Contents -- List of Illustrations -- Preface -- 1. The Phone Call -- 2. Accidental Scientist -- 3. People and Pestilence -- 4. Opening the Black Box of Cancer -- 5. Paradoxical Strife -- Notes -- Credits -- Index |
| Record Nr. | UNINA-9910969413803321 |
Bishop J. Michael <1936->
|
||
| Cambridge, MA ; ; London, : Harvard University Press, 2004 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecules Engineered Against Oncogenic Proteins and Cancer : Discovery, Design, and Development
| Molecules Engineered Against Oncogenic Proteins and Cancer : Discovery, Design, and Development |
| Autore | Corey E. J |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2023 |
| Descrizione fisica | 1 online resource (391 pages) |
| Altri autori (Persone) | WuYong-Jin |
| Soggetto topico |
Protein kinases - Inhibitors
Oncogenes |
| ISBN |
9781394207145
139420714X 9781394207091 1394207093 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright -- Contents -- Preface -- Chapter 1. Introduction -- 1.1 Types of Protein Kinases -- 1.2 Protein Kinase Domains -- 1.3 ATP-Binding Site -- 1.4 Types of Kinase Inhibitors -- 1.5 Brief History of Small-molecule kinase Inhibitors -- 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors -- 1.7 Approved Kinase Inhibitors -- Chapter 2. BCR-ABL Inhibitors -- 2.1 Imatinib* -- 2.2 Nilotinib* -- 2.3 Dasatinib* -- 2.4 Bosutinib* -- 2.5 Ponatinib* -- 2.6 Olvermbatinib** -- 2.7 Asciminib* -- Chapter 3. BTK Inhibitors -- 3.1 Ibrutinib* -- 3.2 Acalabrutinib* -- 3.3 Zanubrutinib* -- 3.4 Tirabrutinib** -- 3.5 Orelabrutinib** -- Chapter 4. EGFR/HER Family Inhibitors -- 4.1 Gefitinib* -- 4.2 Erlotinib * -- 4.3 Icotinib** -- 4.4 Afatinib* -- 4.5 Dacomitinib* -- 4.6 Osimertinib* -- 4.7 Mobocertinib* -- 4.8 Lapatinib* -- 4.9 Tucatinib* -- 4.10 Neratinib* -- Chapter 5. VEGFR/Multikinase Inhibitors -- 5.1 Sorafenib* -- 5.2 Regorafenib* -- 5.3 Sunitinib* -- 5.4 Pazopanib* -- 5.5 Axitinib* -- 5.6 Nintedanib* -- 5.7 Apatinib** -- 5.8 Lenvatinib* -- 5.9 Tovozanib* -- Chapter 6. CDK4/6 Inhibitors -- 6.1 Palbociclib* -- 6.2 Ribociclib* -- 6.3 Abemaciclib* -- 6.4 Trilaciclib* -- Chapter 7. JAK Inhibitors -- 7.1 Tofacitinib* -- 7.2 Baricitinib* -- 7.3 Peficitinib** -- 7.4 Upadacitinib* -- 7.5 Delgocitinib** -- 7.6 Filgotinib** -- 7.7 Abrocitinib* -- 7.8 Ruxolitinib* -- 7.9 Fedratinib* -- 7.10 Pacritinib* -- 7.11 Ritlecitinib# -- 7.12 Brepocitinib# -- 7.13 Ropsacitinib# -- Chapter 8. Allosteric TYK2 Inhibitors -- 8.1 Deucravacitinib* -- Chapter 9. ALK/multikinase Inhibitors -- 9.1 Crizotinib* -- 9.2 Ceritinib* -- 9.3 Alectinib* -- 9.4 Brigatinib* -- 9.5 Lorlatinib* -- Chapter 10. BRAF/Multikinase Inhibitors -- 10.1 Vemurafenib* -- 10.2 Dabrafenib* -- 10.3 Encorafenib* -- Chapter 11. MEK Inhibitors -- 11.1 Trametinib* -- 11.2 Cobimetinib*.
11.3 Binimetinib* -- 11.4 Selumetinib* -- Chapter 12. RET/Multikinase Inhibitors -- 12.1 Vandetanib* -- 12.2 Cabozantinib* -- 12.3 Selpercatinib* -- 12.4 Pralsetinib* -- Chapter 13. FGFR Inhibitors -- 13.1 Erdafitinib* -- 13.2 Pemigatinib* -- 13.3 Infigratinib* -- 13.4 Futibatinib* -- Chapter 14. PI3K Inhibitors -- 14.1 Alpelisib* -- 14.2 Idelalisib* -- 14.3 Duvelisib* -- 14.4 Umbralisib* -- 14.5 Copanlisib* -- Chapter 15. TRK/Multikinase Inhibitors -- 15.1 Larotrectinib* -- 15.2 Entrectinib* -- 15.3 Repotrectinib# -- Chapter 16. MET Inhibitors -- 16.1 Capmatinib* -- 16.2 Tepotinib* -- Chapter 17. KIT/PDGFR/Multkinase Inhibitors -- 17.1 Avapritinib* -- 17.2 Ripretinib* -- Chapter 18. FLT3 Inhibitors -- 18.1 Midostaurin* -- 18.2 Gilteritinib* -- Chapter 19. mTOR Inhibitors -- 19.1 Sirolimus* and Analogs -- Chapter 20. Other Kinase Inhibitors -- 20.1 Netarsudil* -- 20.2 Belumosudil* -- 20.3 Fostamatinib* -- 20.4 Pexidartinib* -- Chapter 21. KRAS Inhibitors -- 21.1 Sotorasib* -- 21.2 Adagrasib* -- 21.3 JDQ443# -- Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases -- 22.1 High-quality Leads -- 22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors -- 22.3 Variation of Hinge-binding Nucleus -- 22.4 Macrocyclization -- 22.5 Fragment-based Approach -- 22.6 Covalent Inhibitors -- 22.7 Strategic Structural Modification of Prior Drugs -- 22.8 Exploiting Specific Kinase Pocket to Optimize Selectivity -- 22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties -- Chapter 23. Targeted Molecular Anticancer Therapies - Successes and Challenges -- 23.1 The Beginning -- 23.2 Further Developments -- 23.3 Biomarker-driven Drug Development -- 23.4 Mitigation of Drug Resistance -- 23.5 Miscellaneous Approaches -- 23.6 Discovery Chemistry. Appendix 1. First FDA Approvals by Year -- Appendix 2. Kinase/KRAS Inhibitors in Development -- Appendix 3. Visualization of Differentially Expressed Kinases in Cancer -- Appendix 4. M & -- A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors -- Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors -- EULA. |
| Record Nr. | UNINA-9911020083103321 |
Corey E. J
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2023 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Onco
| Onco |
| Pubbl/distr/stampa | Basel, Switzerland : , : MDPI |
| Descrizione fisica | 1 online resource |
| Disciplina | 610 |
| Soggetto topico |
Oncogenes
Cancer - Treatment |
| ISSN | 2673-7523 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910647286603321 |
| Basel, Switzerland : , : MDPI | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oncogene
| Oncogene |
| Pubbl/distr/stampa | [New York], : Stockton Press |
| Disciplina | 616.994042 |
| Soggetto topico | Oncogenes |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1476-5594 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996518461603316 |
| [New York], : Stockton Press | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||